Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Warning: Keep out of the reach of children
Add solvent slowly along the inner wall of the vial to minimize foaming or peptide denaturation
Figure 1: Changes in body weight from baseline to the end of treatment at week 26 associated with the trial product estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
407 In contrast, the ATTRACTION-4 trial, which investigated nivolumab plus SOX or CAPOX in gastric/EGJ cancer, met its PFS endpoint (HR = 0.68, P = 0.0007) but did not demonstrate a statistically significant improvement in OS (HR = 0.90, P = 0.26), potentially influenced by high rates of subsequent therapy, including ICIs, in the control arm
US$ 20.81
US$ 24.26
US$ 29.28
US$ 27.03
US$ 25.76
US$ 25.85
US$ 22.25
US$ 22.42
US$ 24.77
